Company intelligence / Profile preview

Dianox

Copenhagen, Denmark

Ownership: Private
Employees: ~16
Development stage: Other

Overview

Dianox has developed an AI-powered drug discovery platform targeting undruggable proteins using proprietary DNA and RNA libraries. The company also produces innovative diagnostic self-tests for infectious diseases to improve global health outcomes. No published clinical results are available yet for therapeutic programs; their diagnostic products are reportedly in the market or late-stage development.

Therapeutic areas: OtherInfectious Diseases
Modalities: DNA-based diagnosticsRNA-based diagnosticsAI-driven drug discovery with DNA and RNA libraries for therapeutics
Industry: Biotech

Beyond the preview

Go deeper on Dianox.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dianox.

Explore the full profile